<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Health Select Committee inquiry into Public Health England</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Written evidence from Novartis Pharmaceuticals UK Limited (PHE001</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Funding for the National Haemoglobinopathy Registry (NHR)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt; text-decoration:underline">Novartis Pharmaceuticals has a long-term commitment to developing treatments for iron overload in people with haemoglobinopathies (red cell disorders such as sickle cell disease and thalassaemia major). We are keen to contribute more generally to improving outcomes for patients with this type of disease and are therefore taking this opportunity to highlight an important public health issue to the Committee – the lack of adequate long-term funding for the National Haemoglobinopathies Registry.</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 0pt 18pt; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">1.0</span><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Executive Summary</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 5pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Amongst Public Health England’s (PHE) responsibilities is researching, collecting and analysing data to improve understanding of health and address public health problems. </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">The NHR (National Haemoglobinopathy Registry) is a valuable existing database of UK patients with red cell disorders (mainly sickle cell and thalassaemia major) whose continued funding is currently under threat. We would like to encourage the Health Select Committee to hold Public Health England to account for the provision of adequate and long-term funding for the register to foster research into haemoglobinopathies and improve patient outcomes.</span></li></ul><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt">The public health benefits of having a long-term patient registry are:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It informs clinicians and commissioners about the number, locality and profile (e.g. age, gender, treatment, condition spectrum) of haemoglobinopathy patients, which supports health planning decisions about funding for, and staffing of, NHS services</span></li><li style="font-family:Symbol; font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It is a key resource for supporting patient enrolment into clinical trials, and underpins collaborative efforts between clinicians and researchers to improve patient outcomes</span></li><li style="font-family:Symbol; font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It can operate as a patient information and feedback site, providing invaluable perspectives to clinicians and managers in improving health outcomes </span></li></ul><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">The above can only be achieved if the registry is properly funded both now and in the future</span><span style="font-family:'Times New Roman'; font-size:12pt"> – long-term annual patient reviews are vital in achieving accurate outcome data, including diagnosis, treatment and complications, as well as real time reporting of adverse events, such as deaths, stroke, sepsis and emergency admission, that can then inform planning of services to improve health outcomes.</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">2.0</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Introduction to the NHR</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Amongst PHE’s responsibilities is researching, collecting and analysing data to improve understanding of health and address public health problems.</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The National Haemoglobinopathy Registry (NHR) is a consented database of UK patients with red cell disorders (sickle cell and thalassaemia) containing details of almost 6,500 </span><span style="font-family:'Times New Roman'; font-size:12pt">patients.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:12pt"> The NHR collects information on diagnosis, treatment and risk factors for disease complications such as use of iron chelation therapy. The database also collects information on causes of death. The database is only available on the secure NHS intranet to clinicians who register their centre and is managed by the Steering Group of the NHR.</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The central aim of the database is to improve patient care across the UK by providing invaluable anonymous information to Haemoglobinopathy centres and specialist commissioners in order to improve services. This data is essential for healthcare planning, identifying patient numbers and research into improved treatment methods. Any data used for these purposes is presented as anonymous group-reports and cannot be traced back to individual patients.</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">To summarise, the NHR system provides three separate services: the </span><a href="http://www.nhr.nhs.uk/default.aspx"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:12pt; text-decoration:underline">NHR public Internet website</span></a><span style="font-family:'Times New Roman'; font-size:12pt">, the NHR secure database, which provides an easy way for Sickle Cell and Thalassaemia clinicians and centres to record information about their patients, and finally the NHR secure Information Service, which provides anonymous summary information to treatment centres and commissioners.</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">3.0</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Current Situation and Moving Forward</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt">Since April 2013 the NHR has been funded by specialist commissioning from PHE but we understand that there is currently no guaranteed funding for next year, or any subsequent years. The inclusion of references to the registry in the service specification</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:12pt"> may be reversed and even if they stay in this does not guarantee adequate, sustainable, future funding of the NHR. The service specification will only guarantee that the data is collected and not what happens to it afterwards. Indeed the NHR currently receives significantly less funding than </span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:12pt">registries for comparable diseases, such as haemophilia. </span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">In order to transform the NHR into a sustainable registry that is as effective as the Haemophilia registry requires a commitment from PHE to long-term funding to provide stability and scope for further improvements as well as the opportunity for annual patient reviews and delivery of more accurate patient outcome data.</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:12pt">The public health benefits of having a long-term registry are:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It informs clinicians and commissioners about the number, locality and profile (e.g. age, gender, treatment, condition spectrum) of haemoglobinopathy patients, which supports health planning decisions about funding for, and staffing of, NHS services</span></li><li style="font-family:Symbol; font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It is a key resource for supporting patient enrolment into clinical trials, and underpins collaborative efforts between clinicians and researchers to improve patient outcomes</span></li><li style="font-family:Symbol; font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 28.52pt; padding-left:7.48pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">It can operate as a patient information and feedback site, providing invaluable perspectives to clinicians and managers in improving health outcomes</span></li></ul><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Currently, the viability of the NHR is under threat due to this uncertainty about future funding and we would therefore </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">like to encourage the Health Select Committee to hold Public Health England to account for the provision of adequate and long-term funding for the register to foster research into haemoglobinopathies and improve patient outcomes in line with its core responsibilities.</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">November 2013</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Times New Roman'; font-size:10pt"> http://www.nhr.nhs.uk/</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:'Times New Roman'; font-size:10pt"> NHS England: Service Specification for Specialised Haemaglobinopathies Care (All ages). Available at: </span><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/b08-speci-serv-haemo.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; text-decoration:underline">http://www.england.nhs.uk/wp-content/uploads/2013/06/b08-speci-serv-haemo.pdf</span></a><span style="font-family:'Times New Roman'; font-size:10pt">, accessed on 7 November 2013</span></p></body></html>